View abstract

Cet abstract a été assigné à session AOB Free Papers

Type de présentation	Oral presentation
Titre	Prospective comparison between Cyclosporine eye drops dissolved in EvoTears® versus in castor oil in the treatment of ocular surface inflammatory diseases

But	Cyclosporine A (CsA) eye drops are used in difficult ocular surface inflammatory diseases (OSID) and formulated in oil-based solvents (which are poorly tolerated) at the hospital pharmacy. This study aimed to compare the effectiveness and tolerance of CsA eye drops dissolved in Perfluorohexyloctane (H6F8 – CsA-H6F8) versus in castor oil (CO – CsA-CO) in order to obtain a new formulation feasible in public pharmacies and therefore more accessible to patients. The secondary objective was to determine the stability of CsA in H6F8.
Méthodes	This randomized double-blind monocentric study was conducted in the Ophthalmology department of Erasme Hospital. Main inclusion criteria was an OSID with a need of CsA and main exclusion criteria was pregnancy and/or breastfeeding. Eleven participants with allergic conjunctivitis (AC) and 2 with dry-eye-syndrome (DES) were included. Both eyes of each patient received daily for 4 consecutive weeks either CsA-H6F8 or CsA-CO. Effectiveness and tolerance were determined using different surface scores, photographs and a questionnaire, all performed before and after the treatment. CsA stability was determined by high-performance-liquid-chromatography/mass spectrometry.
Résultats	Résultats : CsA-H6F8 showed a better effectiveness in AC but not for DES while the tolerance seems to be worse for CsA-H6F8. These differences were not statistically significant. CsA stability could not be determined due to aberrant results.
Conclusion	Larger study and a longer follow-up might confirm these results. CsA stability might be determined using a UV-spectrophotometry. Future adjuvant is needed to increase the solubility and tolerance of CsA. An easier accessibility of CsA eye drops might decrease the overprescription of corticosteroids and its considerable side effects.
Conflit d'intérêt	Non

Auteur 1

Nom	MANILIHO
Initiales	J
Institut	Erasme hospital
Ville	Brussels

Auteur 2

Nom	ES-SAFIA
Initiales	M

Auteur 3

Nom	LIEVINB
Initiales	V

Auteur 4

Nom	HAKAMIA
Initiales	S

Auteur 5

Nom	MOTULSKY
Initiales	E